Tada Hiroomi
Known title: Chief Medical OfficerCIK: 0001880593
Associated companies
Transaction History
| TYRA | ▲ Buy | Grant | 1,968 | $13K | 3/15/2024 | View on chart |
| TYRA | ▲ Buy | Grant | 1,337 | $9K | 9/15/2023 | View on chart |
| TYRA | ▲ Buy | Grant | 1,893 | $12K | 3/15/2023 | View on chart |
| TYRA | ▲ Buy | Grant | 612 | $5K | 9/15/2022 | View on chart |
| TYRA | ▲ Buy | Grant | 2,703 | $23K | 3/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop
Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.